BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S. Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome. Chem Res Toxicol 2016;29:1591-601. [DOI: 10.1021/acs.chemrestox.6b00215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. Biomed Pharmacother 2023;159:114232. [PMID: 36630849 DOI: 10.1016/j.biopha.2023.114232] [Reference Citation Analysis]
2 Canille RMDS, Pinto MH, Galisteu KJ, Czorny RC, Bertolazzi LG, Faria TV. Adverse dermatoneurological events and impacts on daily activities of patients with gastrointestinal neoplasms undergoing chemotherapy. Rev Bras Enferm 2023;76:e20220161. [PMID: 36722645 DOI: 10.1590/0034-7167-2022-0161] [Reference Citation Analysis]
3 Ge C, Huang X, Zhang S, Yuan M, Tan Z, Xu C, Jie Q, Zhang J, Zou J, Zhu Y, Feng D, Zhang Y, Aa J. In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer. Cancer Cell Int 2023;23:14. [PMID: 36717845 DOI: 10.1186/s12935-023-02853-6] [Reference Citation Analysis]
4 Li X, Cui D, Xiong J, Dang Q, Wen Q, Yan M, Li H, Jiang X, Lin C, Xie X, Wang T, Xiang L, Wang Y, Zheng L. Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients. Clin Pharmacol Drug Dev 2023. [PMID: 36642942 DOI: 10.1002/cpdd.1202] [Reference Citation Analysis]
5 Canille RMDS, Pinto MH, Galisteu KJ, Czorny RC, Bertolazzi LG, Faria TV. Eventos dermatoneurológicos adversos e impactos nas atividades cotidianas de pacientes com neoplasias gastrointestinais em quimioterapia. Rev Bras Enferm 2023;76. [DOI: 10.1590/0034-7167-2022-0161pt] [Reference Citation Analysis]
6 Ghodousi M, Karbasforooshan H, Arabi L, Elyasi S. Silymarin as a preventive or therapeutic measure for chemotherapy and radiotherapy-induced adverse reactions: a comprehensive review of preclinical and clinical data. Eur J Clin Pharmacol 2023;79:15-38. [PMID: 36450892 DOI: 10.1007/s00228-022-03434-8] [Reference Citation Analysis]
7 Quintanilha JCF, Geyer S, Etheridge AS, Racioppi A, Hammond K, Crona DJ, Peña CE, Jacobson SB, Marmorino F, Rossini D, Cremolini C, Sanoff HK, Abou-Alfa GK, Innocenti F. KDR genetic predictor of toxicities induced by sorafenib and regorafenib. Pharmacogenomics J 2022;22:251-7. [PMID: 35484400 DOI: 10.1038/s41397-022-00279-3] [Reference Citation Analysis]
8 Yuan J, Khan SU, Luo J, Jiang Y, Yang Y, Yan J, Tong Q. Biosynthetic Silver Nanoparticles Inhibit the Malignant Behavior of Gastric Cancer Cells and Enhance the Therapeutic Effect of 5-Fluorouracil by Promoting Intracellular ROS Generation and Apoptosis. Pharmaceutics 2022;14. [PMID: 36297544 DOI: 10.3390/pharmaceutics14102109] [Reference Citation Analysis]
9 Whorton AE, Razzak AN, Jha P. Hand-Foot Syndrome Presentation Post-Capecitabine Treatment in a Black Patient. Cureus 2022. [DOI: 10.7759/cureus.26891] [Reference Citation Analysis]
10 Santos-Leite ÉGD, Sacramento LV, Santana AM, Dantas JBL, Carrera M, Martins GB. Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome. Braz Dent J 2022;33:97-102. [PMID: 36043574 DOI: 10.1590/0103-6440202204711] [Reference Citation Analysis]
11 Daldoul M, Korbi M, Ben Salah N, Bellalah A, Belhadjali H, Zili J. Hand-foot syndrome like eruption following mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol 2022. [PMID: 35762924 DOI: 10.1111/jdv.18338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Nishioka S, Watanabe T, Asano M, Yamamoto T, Kawakami K, Yada S, Aramaki E, Yajima H, Kizaki H, Hori S. Identification of hand-foot syndrome from cancer patients’ blog posts: BERT-based deep-learning approach to detect potential adverse drug reaction symptoms. PLoS ONE 2022;17:e0267901. [DOI: 10.1371/journal.pone.0267901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rodríguez-garzotto A, Iglesias-docampo L, Díaz-garcía CV, Ruppen I, Ximénez-embún P, Gómez C, Rodríguez-peralto JL, de Frutos JO, Lopez-martin JA, Grávalos C, Cortés-funes H, Agulló-ortuño MT. Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies. Ther Adv Med Oncol 2022;14:175883592210869. [DOI: 10.1177/17588359221086911] [Reference Citation Analysis]
14 He X, Wang J, Wang Q, Liu J, Yang X, He L, Hu H, Zeng S, Yu L, Qiu Y, Lou Y. P38 MAPK, NF-κB, and JAK-STAT3 Signaling Pathways Involved in Capecitabine-Induced Hand-Foot Syndrome via Interleukin 6 or Interleukin 8 Abnormal Expression. Chem Res Toxicol 2022. [PMID: 35147423 DOI: 10.1021/acs.chemrestox.1c00317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Li M, Chen J, Liu S, Sun X, Xu H, Gao Q, Chen X, Xi C, Huang D, Deng Y, Zhang F, Gao S, Qiu S, Tao X, Zhai J, Wei H, Yao H, Chen W. Spermine-Related DNA Hypermethylation and Elevated Expression of Genes for Collagen Formation are Susceptible Factors for Chemotherapy-Induced Hand-Foot Syndrome in Chinese Colorectal Cancer Patients. Front Pharmacol 2021;12:746910. [PMID: 34539419 DOI: 10.3389/fphar.2021.746910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Gao Y, Liu Z, Liu Y. Cisplatin combined with capecitabine-induced chemotherapy for local nasopharyngeal carcinoma can improve the quality of life and reduce toxic and side effects. World J Surg Oncol 2021;19:280. [PMID: 34535176 DOI: 10.1186/s12957-021-02393-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ida Bagus B, Agustriani N, Ermawan R, Suwardi S, Sungkar A, Saadhi IR. Moist Exposed Burn Ointment Effectiveness for Capecitabine Associated Grade II and III Hand Foot Syndrome on Stage III Colonic. Open Access Maced J Med Sci 2021;9:971-974. [DOI: 10.3889/oamjms.2021.6959] [Reference Citation Analysis]
18 Li M, Sun X, Yao H, Chen W, Zhang F, Gao S, Zou X, Chen J, Qiu S, Wei H, Hu Z, Chen W. Genomic methylation variations predict the susceptibility of six chemotherapy related adverse effects and cancer development for Chinese colorectal cancer patients. Toxicol Appl Pharmacol 2021;427:115657. [PMID: 34332992 DOI: 10.1016/j.taap.2021.115657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Alam W, Bouferraa Y, Haibe Y, Mukherji D, Shamseddine A. Management of colorectal cancer in the era of COVID-19: Challenges and suggestions. Sci Prog 2021;104:368504211010626. [PMID: 33878982 DOI: 10.1177/00368504211010626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
20 Hiromoto S, Kawashiri T, Yamanaka N, Kobayashi D, Mine K, Inoue M, Uchida M, Shimazoe T. Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. Sci Rep 2021;11:8964. [PMID: 33903667 DOI: 10.1038/s41598-021-88460-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Silva D, Ferreira MS, Sousa-lobo JM, Cruz MT, Almeida IF. Anti-Inflammatory Activity of Calendula officinalis L. Flower Extract. Cosmetics 2021;8:31. [DOI: 10.3390/cosmetics8020031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chen J, Wang Z. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs. J Oncol Pharm Pract 2021;27:919-29. [PMID: 33874817 DOI: 10.1177/10781552211009291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Nakamura N, Shiraiwa H, Haruna Y, Ichijima T, Takeda T, Hasegawa K, Kusumoto M, Yano Y. Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand-foot syndrome in cancer patients: a retrospective study. J Pharm Health Care Sci 2021;7:8. [PMID: 33641672 DOI: 10.1186/s40780-021-00191-1] [Reference Citation Analysis]
24 Grinnell M, Rieger KE, Katsumoto TR, Kwong BY, Zaba LC. Anti-cancer therapy related hand-foot syndrome in patients with systemic sclerosis: Case series and literature review. Current Problems in Cancer: Case Reports 2020;1:100021. [DOI: 10.1016/j.cpccr.2020.100021] [Reference Citation Analysis]
25 Lesage C, Guillot B, Sibaud V. Toxicidad cutánea de la quimioterapia del cáncer. EMC - Dermatología 2020;54:1-18. [DOI: 10.1016/s1761-2896(20)44322-5] [Reference Citation Analysis]
26 Yang S, Tseng S, Wang C, Young T, Chen K, Shieh M. Magnetic nanomedicine for CD133-expressing cancer therapy using locoregional hyperthermia combined with chemotherapy. Nanomedicine 2020;15:2543-61. [DOI: 10.2217/nnm-2020-0222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Yu R, Wu X, Jia L, Lou Y. Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial. Integr Cancer Ther 2020;19:1534735420928466. [PMID: 32597691 DOI: 10.1177/1534735420928466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Novotná V, Pohanková D, Sirák I, Petera J. Adrese efect of chemotherapy. Onkologie 2020;14:13-17. [DOI: 10.36290/xon.2020.050] [Reference Citation Analysis]
29 Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 2020;14:442. [PMID: 32431787 DOI: 10.4081/oncol.2020.442] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
30 Shiraishi T, Nishizawa Y, Nakajima M, Kado R, Ikeda K, Tsukada Y, Sasaki T, Ito M. Risk factors for the incidence and severity of peristomal skin disorders defined using two scoring systems. Surg Today 2020;50:284-91. [DOI: 10.1007/s00595-019-01876-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Karimi E, Gharib B, Rostami N, Navidpour L, Afshar M. Clinical efficacy of a topical polyherbal formulation in the management of fluorouracil -associated hand-foot syndrome. Journal of Herbal Medicine 2019;17-18:100270. [DOI: 10.1016/j.hermed.2019.100270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Peccerillo F, Pampena R, Giannetti L, Pellacani G, Longo C. Capecitabine-induced eruptive acral hyperpigmentation: Clinical and dermoscopic evaluation of two cases. Dermatol Ther 2019;32:e12853. [PMID: 30748073 DOI: 10.1111/dth.12853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Wu J, Markova A, Lacouture ME. Dermatologic Adverse Events from Cancer Treatments. Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions 2019. [DOI: 10.1007/978-981-13-1489-6_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Lou Y, Wang Q, Zheng J, Wang X, Jiang W, Zheng Y, Zhao Q, Qiu Y, Zeng S. Identification of the Novel Capecitabine Metabolites in Capecitabine-Treated Patients with Hand-Foot Syndrome. Chem Res Toxicol 2018;31:1069-79. [PMID: 30230321 DOI: 10.1021/acs.chemrestox.8b00150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Liu R, Jiang Y, Hu X, Wu J, Jiang W, Jin G, Luan Y. A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors. Int J Pharm 2018;552:111-8. [PMID: 30268848 DOI: 10.1016/j.ijpharm.2018.09.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
36 Watanabe A, Yang CC, Cheung WY. Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients. Med Oncol 2018;35:125. [PMID: 30117039 DOI: 10.1007/s12032-018-1188-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C. Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population. Drugs Real World Outcomes 2018;5:161-7. [PMID: 29934933 DOI: 10.1007/s40801-018-0138-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Deng B, Sun W. Herbal medicine for hand-foot syndrome induced by fluoropyrimidines: A systematic review and meta-analysis. Phytother Res 2018;32:1211-28. [PMID: 29682836 DOI: 10.1002/ptr.6068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Komatsu H, Yagasaki K, Hamamoto Y, Takebayashi T. Falls and Physical Inactivity in Patients with Gastrointestinal Cancer and Hand-Foot Syndrome. Asia Pac J Oncol Nurs 2018;5:307-13. [PMID: 29963593 DOI: 10.4103/apjon.apjon_8_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front Pharmacol 2017;8:736. [PMID: 29075194 DOI: 10.3389/fphar.2017.00736] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
41 Cohen PR. Capecitabine-Associated Loss of Fingerprints: Report of Capecitabine-Induced Adermatoglyphia in Two Women with Breast Cancer and Review of Acquired Dermatoglyphic Absence in Oncology Patients Treated with Capecitabine. Cureus 2017;9:e969. [PMID: 28191373 DOI: 10.7759/cureus.969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]